Recommended Initial Treatment for Depression
For moderate to severe major depressive disorder, initiate treatment with either cognitive behavioral therapy (CBT) monotherapy OR a second-generation antidepressant monotherapy, with combination therapy reserved for patients who prefer it or have more severe/chronic presentations. 1
Treatment Algorithm by Severity
Mild Major Depressive Disorder
- Start with CBT monotherapy 1
- Second-generation antidepressants are an alternative if CBT is not feasible or preferred by the patient
Moderate to Severe Major Depressive Disorder
First-Line Options (choose one):
- CBT monotherapy
- Second-generation antidepressant monotherapy
- Combination therapy (CBT + second-generation antidepressant)
1 provides strong evidence (moderate certainty) that CBT and second-generation antidepressants have similar efficacy as monotherapies. The 2023 ACP guideline explicitly recommends monotherapy as the initial approach, with combination therapy as a conditional recommendation for those who prefer it.
Combination therapy offers advantages for sustained response. 2 demonstrates that combination treatment results in more sustained response than pharmacotherapy alone (OR=2.52 when continued; OR=1.80 when followed by discretionary treatment), translating to 12-16 percentage point improvements in sustained response rates. This makes combination therapy particularly valuable for severe or chronic depression 3.
Choosing Between Treatment Modalities
Consider these factors when selecting initial treatment:
- Adverse effect profile: Antidepressants have higher discontinuation rates due to adverse events compared to psychotherapy 4
- Specific symptoms: Insomnia, hypersomnia, or appetite changes may influence medication choice
- Cost and accessibility: CBT requires trained therapists and may have limited availability
- Patient preference: Critical determinant of adherence and outcomes
- Comorbidities: Concurrent medications and medical conditions affect antidepressant selection
- Long-term outcomes: Psychotherapy demonstrates more enduring effects than pharmacotherapy alone 2
Evidence Quality and Nuances
The 2023 ACP guideline 1 represents the most recent high-quality evidence, based on a systematic review through August 2022 4. This guideline provides strong recommendations for monotherapy (moderate certainty evidence) but only conditional recommendations for combination therapy (low certainty evidence).
Important caveat: While 4 found similar benefits across most treatments, the certainty of evidence remains low for many comparisons. The network meta-analysis included 65 randomized trials but noted methodological limitations and dosing inequalities.
The 2024 JAMA review 3 corroborates these findings, reporting that 21 different antidepressants show small to medium effects (SMD 0.23-0.48) and multiple psychotherapy modalities demonstrate medium to large effects (SMD 0.50-0.73).
Second-Generation Antidepressants
All second-generation antidepressants have similar efficacy 4, 3. Selection should be based on:
- Side effect profile
- Drug interactions
- Prior response history
- Cost considerations
Common classes include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants.
Psychotherapy Options Beyond CBT
While the ACP guideline 1 specifically recommends only CBT (citing insufficient evidence for other modalities), the VA/DoD 5 and other guidelines recognize multiple effective psychotherapies. 3 demonstrates that behavioral activation, problem-solving therapy, interpersonal therapy, brief psychodynamic therapy, and mindfulness-based psychotherapy all show medium-sized effects (SMD 0.50-0.73).
This represents a key divergence in guidelines, likely reflecting the ACP's more conservative evidence threshold versus the VA/DoD's broader inclusion of psychotherapy modalities.
Critical Implementation Points
Systematic monitoring significantly improves outcomes. Collaborative care programs with systematic follow-up increase treatment effectiveness (SMD 0.42) 3. This means:
- Use structured severity assessments at each visit
- Monitor for treatment response every 2-4 weeks
- Assess for suicidal ideation, bipolar symptoms, and substance use
- Evaluate for comorbid anxiety disorders
Common pitfall: Starting treatment without establishing a monitoring plan. Up to 70% of patients do not achieve remission with initial treatment 4, making systematic assessment essential for timely treatment adjustments.